Analysis confirms crizotinib's second-line efficacy in Asian NSCLC patients
This article was originally published in Scrip
Executive Summary
An analysis of data from a Phase III clinical trial with Pfizer's Xalkori (crizotinib) has confirmed the efficacy and safety of the oral anaplastic lymphoma kinase (ALK) inhibitor in Asian patients with advanced ALK-positive non-small cell lung cancer (NSCLC).